Atara Biotherapeutics (ATRA) Short Interest Ratio & Short Volume $6.90 -0.10 (-1.43%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$7.12 +0.22 (+3.25%) As of 05/21/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Atara Biotherapeutics Short Interest DataAtara Biotherapeutics (ATRA) has a short interest of 522,100 shares, representing 13.67% of the float (the number of shares available for trading by the public). This marks a -21.16% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.5, indicating that it would take 8.5 days of the average trading volume of 124,560 shares to cover all short positions.Current Short Interest522,100 sharesPrevious Short Interest662,200 sharesChange Vs. Previous Month-21.16%Dollar Volume Sold Short$4.17 millionShort Interest Ratio8.5 Days to CoverLast Record DateApril 30, 2025Outstanding Shares5,961,000 sharesFloat Size3,820,000 sharesShort Percent of Float13.67%Today's Trading Volume67,446 sharesAverage Trading Volume124,560 sharesToday's Volume Vs. Average54% Short Selling Atara Biotherapeutics? Sign up to receive the latest short interest report for Atara Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATRA Short Interest Over TimeATRA Days to Cover Over TimeATRA Percentage of Float Shorted Over Time Atara Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2025522,100 shares $4.17 million -21.2%13.7%8.5 $7.99 4/15/2025662,200 shares $3.96 million -0.7%17.6%6.7 $5.98 3/31/2025666,800 shares $3.96 million -7.8%17.6%3.6 $5.94 3/15/2025723,300 shares $5.24 million +1.2%19.0%3.7 $7.25 2/28/2025715,100 shares $4.94 million +6.0%18.8%3.5 $6.91 2/15/2025674,600 shares $5.79 million -4.5%18.1%3.3 $8.59 1/31/2025706,500 shares $6.27 million +29.0%18.9%3.3 $8.88 1/15/2025547,800 shares $7.21 million +2.7%12.7%2.7 $13.16 12/31/2024533,600 shares $7.10 million -3.3%12.4%4.8 $13.31 12/15/2024551,500 shares $5.70 million +1.4%13.0%5.4 $10.33 Get the Latest News and Ratings for ATRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/2024544,000 shares $6.62 million +4.7%13.0%5.1 $12.18 11/15/2024519,500 shares $6.23 million -18.4%12.4%3.5 $12.00 10/31/2024636,300 shares $5.67 million -0.5%16.0%4.6 $8.91 10/15/2024639,200 shares $5.36 million +21.4%16.1%5.4 $8.38 9/30/2024526,400 shares $4.28 million +13.7%13.3%4.5 $8.13 9/15/2024463,000 shares $4.50 million +12.8%12.6%3.6 $9.72 8/31/2024410,500 shares $3.12 million +8.5%11.0%3.2 $7.60 8/15/2024378,500 shares $2.59 million +5.0%9.4%4.7 $6.83 7/31/2024360,500 shares $3.54 million -33.2%9.0%4.5 $9.83 7/15/2024540,000 shares $6.03 million -6.1%13.4%6.7 $11.16 6/30/2024575,300 shares $4.89 million +33.5%14.4%7.6 $8.50 6/15/2024431,000 shares $5.51 million -96.2%10.8%7.2 $12.78 5/31/202411,270,000 shares $6.32 million -3.0%N/A8.5 $0.56 5/15/202411,620,000 shares $7.44 million -2.2%N/A7.2 $0.64 4/30/202411,880,000 shares $8.20 million +3.8%N/A6.9 $0.69 4/15/202411,450,000 shares $7.77 million +2.0%N/A4.4 $0.68 3/31/202411,230,000 shares $7.79 million +1.8%N/A3.7 $0.69 3/15/202411,030,000 shares $6.85 million +8.8%N/A3.2 $0.62 2/29/202410,140,000 shares $7.89 million -6.7%N/A2.8 $0.78 2/15/202410,870,000 shares $8.39 million +44.4%N/A2.9 $0.77 1/31/20247,530,000 shares $4.70 million +2.7%N/A1.3 $0.62 1/15/20247,330,000 shares $5.27 million -20.2%N/A1.4 $0.72 12/31/20239,190,000 shares $4.71 million -9.3%N/A1.9 $0.51 12/15/202310,130,000 shares $6.08 million -8.8%N/A2.2 $0.60 11/30/202311,110,000 shares $7.33 million +36.2%N/A2.8 $0.66 11/15/20238,160,000 shares $3.10 million -34.7%N/A2.2 $0.38 10/31/202312,490,000 shares $16.11 million +1.8%N/A6.1 $1.29 10/15/202312,270,000 shares $18.90 million +6.3%N/A10.5 $1.54 9/30/202311,540,000 shares $17.08 million -1.1%N/A9.5 $1.48 9/15/202311,670,000 shares $17.86 million +1.2%N/A9.7 $1.53July 2025 Rule Change to Impact Retirement Investors (Ad)There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.Yes, Send Me My FREE Retirement Guide 8/31/202311,530,000 shares $16.83 million -5.4%N/A7.5 $1.46 8/15/202312,190,000 shares $22.43 million -5.9%N/A6.9 $1.84 7/31/202312,950,000 shares $28.62 million +2.6%N/A6.9 $2.21 7/15/202312,620,000 shares $23.09 million +7.9%N/A6.7 $1.83 6/30/202311,700,000 shares $18.84 million -11.4%N/A6 $1.61 6/15/202313,200,000 shares $28.25 million +4.6%N/A7 $2.14 5/31/202312,620,000 shares $19.31 million -11.0%N/A7.6 $1.53 5/15/202314,180,000 shares $31.20 million -20.3%N/A10 $2.20 4/30/202317,790,000 shares $48.21 million -7.4%N/A13.8 $2.71 4/15/202319,210,000 shares $51.67 million -3.8%N/A15.9 $2.69 3/31/202319,960,000 shares $57.88 million +19.5%N/A17.1 $2.90 3/15/202316,700,000 shares $51.44 million +18.7%N/A13.1 $3.08 2/28/202314,070,000 shares $56.98 million +0.4%N/A11.3 $4.05 2/15/202314,010,000 shares $63.47 million -1.3%N/A11.4 $4.53 1/31/202314,190,000 shares $71.94 million +4.1%N/A10.3 $5.07 1/15/202313,630,000 shares $53.02 million +4.8%N/A9.5 $3.89 12/30/202213,010,000 shares $42.67 million +5.0%N/A9.1 $3.28 12/15/202212,390,000 shares $42.87 million +1.2%N/A8.4 $3.46 11/30/202212,240,000 shares $55.45 million +1.6%N/A8.4 $4.53 11/15/202212,050,000 shares $60.37 million +1.1%N/A7.7 $5.01 10/31/202211,920,000 shares $55.55 million +0.2%N/A6.9 $4.66 10/15/202211,900,000 shares $44.39 million -3.4%N/A5.7 $3.73 9/30/202212,320,000 shares $46.57 million -0.2%N/A4.6 $3.78 9/15/202212,350,000 shares $58.05 million +10.2%N/A4.7 $4.70 8/31/202211,210,000 shares $44.95 million -0.6%N/A4.4 $4.01 8/15/202211,280,000 shares $60.24 million +7.0%N/A4.7 $5.34 7/31/202210,540,000 shares $31.94 million +31.1%N/A4.8 $3.03 7/15/20228,040,000 shares $30.95 million -24.9%N/A4.4 $3.85 6/30/202210,700,000 shares $83.35 million -5.1%N/A9.2 $7.79 6/15/202211,270,000 shares $62.55 million -3.9%N/A10.2 $5.55 5/31/202211,730,000 shares $61.00 million +6.4%N/A11 $5.20 5/15/202211,020,000 shares $0.00 -6.5%N/A9.9 $0.00 4/30/202211,790,000 shares $74.98 million +6.0%N/A11.7 $6.36 4/15/202211,120,000 shares $89.07 million +14.3%N/A11.2 $8.01 3/31/20229,730,000 shares $90.39 million +11.3%N/A9.6 $9.29 3/15/20228,740,000 shares $74.38 million +20.6%N/A9 $8.51 2/28/20227,250,000 shares $93.16 million +2.6%N/A7.7 $12.85 2/15/20227,070,000 shares $105.84 million +1.4%N/A8.6 $14.97 1/31/20226,970,000 shares $107.06 million +17.3%N/A8.1 $15.36 1/15/20225,940,000 shares $95.46 million -36.9%N/A7.1 $16.07 12/31/20219,420,000 shares $148.46 million +3.4%N/A11.3 $15.76 12/15/20219,110,000 shares $146.03 million +4.8%N/A10.7 $16.03 11/30/20218,690,000 shares $155.46 million -3.3%N/A11 $17.89 11/15/20218,990,000 shares $153.46 million -17.0%N/A10.7 $17.07 10/29/202110,830,000 shares $167.65 million -1.3%N/A13.4 $15.48 10/15/202110,970,000 shares $165.87 million -6.4%13.4%14.3 $15.12 9/30/202111,720,000 shares $209.79 million -6.1%14.4%16.4 $17.90 9/15/202112,480,000 shares $198.43 million +2.1%15.3%16.8 $15.90 8/31/202112,220,000 shares $183.06 million -4.4%15.0%16.2 $14.98 8/13/202112,780,000 shares $159.11 million -2.1%15.7%17.2 $12.45Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 7/30/202113,060,000 shares $166.52 million +8.0%16.1%16.7 $12.75 7/15/202112,090,000 shares $165.39 million +3.7%14.9%14.4 $13.68 6/30/202111,660,000 shares $181.31 million -7.7%14.4%12.4 $15.55 6/15/202112,630,000 shares $176.82 million -0.5%15.6%14.3 $14.00 5/28/202112,690,000 shares $172.08 million -0.7%15.7%13.9 $13.56 5/14/202112,780,000 shares $188.12 million +5.3%N/A13.5 $14.72 4/30/202112,140,000 shares $176.39 million -2.9%N/A13.2 $14.53 4/15/202112,500,000 shares $173.13 million -4.7%N/A0 $13.85 3/31/202113,120,000 shares $186.57 million +12.0%N/A15.2 $14.22 3/15/202111,710,000 shares $197.90 million +5.5%N/A13 $16.90 2/26/202111,100,000 shares $184.37 million -5.5%N/A11.6 $16.61 2/12/202111,740,000 shares $225.64 million -0.7%N/A12.4 $19.22 1/29/202111,820,000 shares $224.58 million +5.0%N/A11.7 $19.00 1/15/202111,260,000 shares $212.25 million -6.1%N/A11.6 $18.85 12/31/202011,990,000 shares $246.03 million -3.8%N/A13.3 $20.52 12/15/202012,460,000 shares $292.56 million +1.0%N/A14.2 $23.48 11/30/202012,340,000 shares $287.15 million -10.1%N/A13.5 $23.27 11/15/202013,730,000 shares $247.83 million -10.3%N/A16.4 $18.05 10/30/202015,310,000 shares $206.69 million -0.8%N/A19.7 $13.50 10/15/202015,440,000 shares $214.15 million +9.0%N/A19.1 $13.87 9/30/202014,170,000 shares $183.64 million +3.3%N/A17.4 $12.96 9/15/202013,720,000 shares $214.58 million -10.1%N/A12.9 $15.64 8/31/202015,260,000 shares $205.70 million +4.5%N/A14.3 $13.48 8/14/202014,610,000 shares $177.80 million +3.5%N/A11 $12.17 7/31/202014,110,000 shares $174.82 million -4.3%N/A8.9 $12.39 7/15/202014,740,000 shares $201.05 million +8.7%N/A9.1 $13.64 6/30/202013,560,000 shares $187.67 million +15.7%N/A7.9 $13.84 6/15/202011,720,000 shares $122.47 million -1.3%N/A7.7 $10.45 5/29/202011,870,000 shares $136.51 million -5.4%N/A8.4 $11.50 ATRA Short Interest - Frequently Asked Questions What is Atara Biotherapeutics' current short interest? Short interest is the volume of Atara Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 522,100 shares of ATRA short. 13.67% of Atara Biotherapeutics' shares are currently sold short. Learn More on Atara Biotherapeutics' current short interest. What is a good short interest ratio for Atara Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATRA shares currently have a short interest ratio of 8.0. Learn More on Atara Biotherapeutics's short interest ratio. What is a good short interest percentage for Atara Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.67% of Atara Biotherapeutics' floating shares are currently sold short. Is Atara Biotherapeutics' short interest increasing or decreasing? Atara Biotherapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 522,100 shares, a decline of 21.2% from the previous total of 662,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Atara Biotherapeutics' float size? Atara Biotherapeutics currently has issued a total of 5,961,000 shares. Some of Atara Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Atara Biotherapeutics currently has a public float of 3,820,000 shares. How does Atara Biotherapeutics' short interest compare to its competitors? 13.67% of Atara Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Atara Biotherapeutics: Molecular Partners AG (0.14%), TransCode Therapeutics, Inc. (5.43%), Journey Medical Co. (3.74%), Silence Therapeutics plc (4.91%), Korro Bio, Inc. (19.34%), Aclaris Therapeutics, Inc. (4.11%), Fate Therapeutics, Inc. (11.64%), Eupraxia Pharmaceuticals Inc. (0.50%), Greenwich LifeSciences, Inc. (16.77%), Protara Therapeutics, Inc. (6.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Atara Biotherapeutics stock? Short selling ATRA is an investing strategy that aims to generate trading profit from Atara Biotherapeutics as its price is falling. ATRA shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Atara Biotherapeutics? A short squeeze for Atara Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATRA, which in turn drives the price of the stock up even further. How often is Atara Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATRA, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies MOLN Short Interest Data RNAZ Short Interest Data DERM Short Interest Data SLN Short Interest Data KRRO Short Interest Data ACRS Short Interest Data FATE Short Interest Data EPRX Short Interest Data GLSI Short Interest Data TARA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATRA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
